SubsidieMeestersSUPRAmolecular Hydrogel Driven Assembly of Designer Heart Tissues
The SUPRAHEART project aims to develop synthetic squaramide-based hydrogels for scalable engineered heart tissues, enhancing reproducibility for pharmaceutical testing and commercialization.
Projectdetails
Introduction
The SUPRAHEART proof-of-concept project aims to use our squaramide-based (SQ) filamentous double network hydrogels for the assembly of engineered heart tissues (EHTs).
Current Limitations
As the current dependency of EHTs on natural materials (e.g., collagen I, Matrigel) limits their large-scale application as cardiac models, their generation using a fully synthetic matrix will provide improved reproducibility, tunability, and scalability. This advancement opens the door for their use as a high-throughput pharmaceutical testing platform.
Project Goals
Expanding on our development of bioactive and mechanically tunable squaramide-based hydrogels for the 3D culture of a broad range of cell types, we will:
- Scale-up the synthesis of the needed squaramide materials.
- Perform in-depth characterization of the structural and mechanical properties of formed hydrogels.
- Develop protocols to generate EHTs in the squaramide hydrogels.
- Evaluate the quality of the formed tissues within the materials.
Business Development
In parallel with these activities, we will prepare a business plan that presents a roadmap to market. This plan will include:
- Detailed market research on these mechanically tunable hydrogels for 3D cell culture.
- Strategies to protect our intellectual property (IP) position.
Commercialization Strategy
Should a patent application be successful, we will collaborate with local partners for commercialization through product licensing.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 150.000 |
| Totale projectbegroting | € 150.000 |
Tijdlijn
| Startdatum | 1-4-2025 |
| Einddatum | 30-9-2026 |
| Subsidiejaar | 2025 |
Partners & Locaties
Projectpartners
- UNIVERSITEIT LEIDENpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
3D-assembly of interactive microgels to grow in vitro vascularized, structured, and beating human cardiac tissues in high-throughputHEARTBEAT aims to create personalized, vascularized millimeter-scale heart tissues using innovative microgel assemblies to enhance stem cell interactions and mimic native environments. | ERC Consolid... | € 2.969.219 | 2022 | Details |
Supramolecular microcapsules for bioreactor expansion of induced pluripotent stem cellsThe SUPROTECT project aims to develop squaramide-based microcapsules for culturing pluripotent stem cells, evaluating their effectiveness while securing intellectual property for potential licensing. | ERC Proof of... | € 150.000 | 2024 | Details |
Supramolecular & Covalent Bonds for Engineering Spatiotemporal Complexity in Hydrogel BiomaterialsThe project aims to develop tough, spatiotemporally responsive hydrogels by combining dynamic supramolecular assemblies with covalent bonds for innovative biomaterial applications. | ERC Consolid... | € 2.000.000 | 2024 | Details |
4D bioprinting shape-morphing tissues using phototunable supramolecular hydrogelsmorphoPRINT aims to develop a dynamic hydrogel platform for bioprinted tissues that enables programmable shape-morphing, facilitating the creation of functional organs through controlled volumetric growth. | ERC Starting... | € 1.499.906 | 2023 | Details |
Surgical optogenetic bioprinting of engineered cardiac muscleLIGHTHEART aims to revolutionize heart failure treatment by developing a surgical bioprinting tool that uses optogenetics to create engineered cardiac muscle directly at the patient's heart. | ERC Starting... | € 1.499.705 | 2023 | Details |
3D-assembly of interactive microgels to grow in vitro vascularized, structured, and beating human cardiac tissues in high-throughput
HEARTBEAT aims to create personalized, vascularized millimeter-scale heart tissues using innovative microgel assemblies to enhance stem cell interactions and mimic native environments.
Supramolecular microcapsules for bioreactor expansion of induced pluripotent stem cells
The SUPROTECT project aims to develop squaramide-based microcapsules for culturing pluripotent stem cells, evaluating their effectiveness while securing intellectual property for potential licensing.
Supramolecular & Covalent Bonds for Engineering Spatiotemporal Complexity in Hydrogel Biomaterials
The project aims to develop tough, spatiotemporally responsive hydrogels by combining dynamic supramolecular assemblies with covalent bonds for innovative biomaterial applications.
4D bioprinting shape-morphing tissues using phototunable supramolecular hydrogels
morphoPRINT aims to develop a dynamic hydrogel platform for bioprinted tissues that enables programmable shape-morphing, facilitating the creation of functional organs through controlled volumetric growth.
Surgical optogenetic bioprinting of engineered cardiac muscle
LIGHTHEART aims to revolutionize heart failure treatment by developing a surgical bioprinting tool that uses optogenetics to create engineered cardiac muscle directly at the patient's heart.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
High-throughput ultrasound-based volumetric 3D printing for tissue engineeringSONOCRAFT aims to revolutionize myocardial cell construct bioprinting by combining rapid volumetric printing with ultrasonic manipulation to create functional cardiac models for drug testing and disease research. | EIC Pathfinder | € 2.999.625 | 2025 | Details |
Next Generation 3D Tissue Models: Bio-Hybrid Hierarchical Organoid-Synthetic Tissues (Bio-HhOST) Comprised of Live and Artificial Cells.Bio-HhOST aims to create bio-hybrid materials with living and artificial cells for dynamic communication, enhancing tissue modeling and reducing animal use in drug research. | EIC Pathfinder | € 1.225.468 | 2024 | Details |
Bringing 3D cardiac tissues to high throughput for drug discovery screensDeveloping a high-throughput 3D cardiac model using microfluidic technology to enhance drug discovery for cardiovascular disease by improving predictive accuracy and scalability. | EIC Transition | € 1.457.500 | 2023 | Details |
PRInted Symbiotic Materials as a dynamic platform for Living Tissues productionPRISM-LT aims to develop a flexible bioprinting platform using hybrid living materials to enhance stem cell differentiation with engineered helper cells for biomedical and food applications. | EIC Pathfinder | € 2.805.403 | 2022 | Details |
building vascular networks and Blood-Brain-Barriers through a Biomimetic manufacturing Technology for the fabrication of Human tissues and ORgansTHOR aims to revolutionize tissue engineering by creating patient-specific, fully functional human tissues using bioinspired mini-robots, eliminating the need for organ transplants. | EIC Pathfinder | € 3.994.150 | 2023 | Details |
High-throughput ultrasound-based volumetric 3D printing for tissue engineering
SONOCRAFT aims to revolutionize myocardial cell construct bioprinting by combining rapid volumetric printing with ultrasonic manipulation to create functional cardiac models for drug testing and disease research.
Next Generation 3D Tissue Models: Bio-Hybrid Hierarchical Organoid-Synthetic Tissues (Bio-HhOST) Comprised of Live and Artificial Cells.
Bio-HhOST aims to create bio-hybrid materials with living and artificial cells for dynamic communication, enhancing tissue modeling and reducing animal use in drug research.
Bringing 3D cardiac tissues to high throughput for drug discovery screens
Developing a high-throughput 3D cardiac model using microfluidic technology to enhance drug discovery for cardiovascular disease by improving predictive accuracy and scalability.
PRInted Symbiotic Materials as a dynamic platform for Living Tissues production
PRISM-LT aims to develop a flexible bioprinting platform using hybrid living materials to enhance stem cell differentiation with engineered helper cells for biomedical and food applications.
building vascular networks and Blood-Brain-Barriers through a Biomimetic manufacturing Technology for the fabrication of Human tissues and ORgans
THOR aims to revolutionize tissue engineering by creating patient-specific, fully functional human tissues using bioinspired mini-robots, eliminating the need for organ transplants.